Botulinum Toxin Type A(Botox®)
Botulinum Toxin Type A(Botox®) is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity
Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm
Clinical Trials (6)
To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity
Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm
Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6